Wednesday, December 11, 2024, 7:15 PM – 9:15 PM CT (8:15 PM – 10:15 PM ET) | San Antonio, Texas

Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer

Part 2 of a 3-Part CME Satellite Symposium Series in Partnership with the 2024 San Antonio Breast Cancer Symposium®

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting
Buffet will open at 7:00 PM CT.

Meeting Room
Grand Ballroom G-M (Third Floor)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Matthew P Goetz, MD
Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
Professor of Oncology and Pharmacology
Enterprise Deputy Director, Translational Research
Mayo Clinic Comprehensive Cancer Center
Director, Mayo Clinic Breast Cancer SPORE
Mayo Clinic
Rochester, Minnesota

Sara A Hurvitz, MD, FACP
Professor
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Head, Division of Hematology/Oncology
UW Medicine
Seattle, Washington

Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy
Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell College of Medicine
New York, New York


Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Seth Wander, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Lilly, Novartis, and Stemline Therapeutics Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting
Buffet will open at 7:00 PM CT.

MODULE 1: Role of CDK4/6 Inhibitors in the Management of Hormone Receptor (HR)-Positive Localized Breast Cancer

  • Clinical and biological factors affecting the choice of adjuvant therapy for HR-positive localized breast cancer
  • Extended follow-up from the Phase III monarchE trial evaluating the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
  • Identification of appropriate candidates for adjuvant abemaciclib and practical considerations with its use
  • Similarities and differences in the designs, eligibility criteria and endpoints of monarchE and the Phase III NATALEE trial evaluating ribociclib with endocrine therapy as adjuvant treatment for HR-positive, HER2-negative localized breast cancer
  • Key efficacy and safety findings with adjuvant ribociclib and endocrine therapy compared to endocrine therapy alone in the NATALEE trial; clinical implications
  • Available data with and ongoing studies evaluating CDK4/6 inhibitors as neoadjuvant therapy for localized ER-positive breast cancer

MODULE 2: First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC)

  • Long-term follow-up, including overall survival data, from pivotal clinical trials of palbociclib, ribociclib and abemaciclib for premenopausal and postmenopausal patients with HR-positive, HER2-negative mBC
  • Key findings from and implications of other recently reported studies, such as SONIA and RIGHT Choice, exploring the efficacy of up-front CDK4/6 inhibitor-based treatment
  • Optimal choice of a CDK4/6 inhibitor and an endocrine partner for HR-positive, HER2-negative mBC; implications of poor-risk features, patient comorbidities and prior therapeutic exposure
  • Spectrum, frequency and severity of clinically relevant adverse events (AEs) reported with palbociclib, ribociclib and abemaciclib; effect on therapeutic selection
  • Available and emerging data sets attempting to define the utility of continuing CDK4/6 inhibitors beyond progression or rechallenging in later lines of therapy; clinical role

MODULE 3: Targeting the PTEN/PI3K/AKT Pathway in Patients with Progressive HR-Positive Breast Cancer

  • Incidence of genomic alterations in the PTEN/PI3K/AKT pathway in patients with HR-positive mBC
  • Biological rationale for inhibiting AKT in HR-positive mBC; mechanism of action of capivasertib
  • Design, eligibility criteria and key endpoints of the Phase III CAPItello-291 study evaluating capivasertib/fulvestrant for HR-positive, HER2-negative mBC progressing on endocrine therapy with or without a CDK4/6 inhibitor
  • Key efficacy and safety data with capivasertib/fulvestrant versus placebo/fulvestrant from CAPItello-291; outcomes for patients with breast cancer with and without PIK3CA/AKT1/PTEN alterations
  • FDA approval of capivasertib for patients with PIK3CA/AKT1/PTEN alterations and role opposite other evidence-based options
  • Spectrum, frequency and severity of toxicities associated with capivasertib; recommended monitoring and management strategies

MODULE 4: Current and Future Management of HR-Positive mBC Harboring PIK3CA Mutations

  • Prevalence and prognostic significance of PIK3CA mutations in HR-positive mBC; optimal timing and methodology for identification
  • Long-term data and practical considerations with alpelisib-based treatment for patients with HR-positive mBC with PIK3CA mutations
  • Available research findings with capivasertib for patients with PIK3CA mutations
  • Management of progressive, HR-positive mBC with PIK3CA mutations; clinical and biological factors affecting therapeutic selection
  • Mechanistic similarities and differences among inavolisib, alpelisib and capivasertib; implications for efficacy and tolerability
  • Key findings from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with endocrine-resistant, HR-positive, HER2-negative mBC with PIK3CA mutations
  • Spectrum, frequency and severity of toxicities documented with inavolisib-containing therapy in INAVO120
  • Potential clinical role of inavolisib in up-front therapy for HR-positive, HER2-negative mBC with a PIK3CA mutation
  • Ongoing Phase III effort in INAVO121 evaluating inavolisib/fulvestrant versus alpelisib/fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations; anticipated completion date

MODULE 5: Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive mBC

  • Incidence of ESR1 mutations in endocrine-resistant breast cancer; optimal approach to assessment
  • Structural, mechanistic and pharmacologic similarities and differences among the various available (eg, fulvestrant, elacestrant) and investigational (eg, camizestrant, imlunestrant) SERDs for breast cancer; implications for efficacy and tolerability
  • Published efficacy and safety results from the Phase III EMERALD trial evaluating elacestrant versus standard-of-care endocrine monotherapy for pretreated HR-positive, HER2-negative mBC; outcomes for patients with and without ESR1 mutations
  • FDA approval of elacestrant for previously treated HR-positive, HER2-negative mBC with ESR1 mutations; optimal incorporation into clinical management algorithms
  • Available findings from early-phase studies, such as SERENA-1, SERENA-2 and EMBER, of the investigational oral SERDs camizestrant and imlunestrant for HR-positive, HER2-negative mBC
  • Comparative side-effect profiles of approved and investigational oral SERDs; optimal monitoring for and management of AEs
  • Ongoing efforts evaluating oral SERDs alone and in combination with other systemic therapies for HR-positive mBC and in earlier disease settings

Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider available clinical trial findings with CDK4/6 inhibitors for localized hormone receptor (HR)-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents may be appropriate.
  • Evaluate biological, patient and treatment-related factors to personalize the selection and sequencing of therapy for HR-positive, HER2-negative metastatic BC (mBC).
  • Review available research documenting the correlation between the presence of various biomarkers (eg, PIK3CA/AKT1/PTEN alterations, ESR1 mutations) and response to specific therapies, and develop optimal molecular testing algorithms for patients with HR-positive mBC.
  • Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for HR-positive mBC, and use this information to appropriately counsel patients regarding the optimal clinical use of these agents.
  • Recall the frequency of PI3K pathway mutations in patients with HR-positive mBC, and employ evidence-based approaches to targeting these abnormalities in patients with PIK3CA-mutated disease.
  • Understand the mechanism of action of, published research findings with and current and future clinical roles for oral SERDs (selective estrogen receptor degraders) for patients with HR-positive mBC.
  • Interrogate published Phase III research documenting the efficacy of AKT inhibitors for patients with progressive HR-positive mBC to determine the current clinical applicability of this approach.
  • Recognize the side effects and toxicities associated with available and investigational endocrine- based therapies used in the care of patients with breast cancer, and identify management and mitigation strategies.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

Dr Goetz — Advisory Committees (to Institution): Biotheranostics Inc, Biotheryx, Blueprint Medicines, EcoR1 Capital LLC, Genentech, a member of the Roche Group, Laekna Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Puma Biotechnology Inc; Consulting Agreements (to Institution): ARC Therapeutics, Lilly, Novartis, Seagen Inc, Stemline Therapeutics Inc; Contracted Research (to Institution, PI): AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Sermonix Pharmaceuticals; Data and Safety Monitoring Boards/Steering Committees (to Institution): AstraZeneca Pharmaceuticals LP, AstraZeneca UK; Intellectual Property: SimBioSys, VeriSIM Life; Speakers Bureau (CME Activities): Curio Science; Travel Support: Lilly; Nonrelevant Financial Relationships: AXIS Medical Education Inc, BroadcastMed, eChinaHealth, Engage Health Media, IDEOlogy Health, MJH Life Sciences, Physician Education Resource (PER), Total Health Conferencing. Dr Hurvitz — Contracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celcuity, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Dignitana AB, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, GSK, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Orinove Inc, Orum Therapeutics, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Zymeworks Inc. Dr Jhaveri — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Debiopharm, Eisai Inc, Genentech, a member of the Roche Group,Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. Dr Kaklamani — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Group, Puma Biotechnology Inc, TerSera Therapeutics LLC; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Sanofi; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc, Seagen Inc. Dr Wander — Advisory Committees: Biovica International AB, Genentech, a member of the Roche Group, Hologic Inc, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Foundation Medicine, Lilly, Novartis; Contracted Research: Genentech, a member of the Roche Group, Lilly, Nuvation Bio, Pfizer Inc, Regor Therapeutics Group, Sermonix Pharmaceuticals; Data and Safety Monitoring Board/Committee: Regor Therapeutics Group; Speakers Bureaus: Guardant Health, Lilly; Nonrelevant Financial Relationship: 2nd.MD.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSeraTherapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Lilly, Novartis, and Stemline Therapeutics Inc.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom G-M (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2024 San Antonio Breast Cancer Symposium is taking place.

 
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2024 San Antonio Breast Cancer Symposium®.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.